The GSP® Neonatal IRT assay allows the quantitative determination of IRT from dried blood spot specimens, and is intended as an aid in screening for cystic fibrosis.
Feature | Specification |
---|---|
Application | Newborn Screening |
The GSP® Neonatal IRT assay allows the quantitative determination of IRT from dried blood spot specimens, and is intended as an aid in screening for cystic fibrosis.
The diagnosis of cystic fibrosis is often based on the symptoms, which may cause considerable delays in the disease intervention, and evidence indicates that early attention may be important in determining the clinical outcome. The amount of the pancreatic enzyme, immunoreactive trypsin (ogen) (IRT) has been shown to be increased in blood of CF patients especially during the first weeks after birth.
GSP Neonatal IRT assay:
The assay is based on a direct sandwich technique where two monoclonal antibodies bind to different epitopes on the target molecule. The fluorescence signal is proportional to the analyte concentration in the sample.
Application |
Newborn Screening
|
---|---|
Brand |
GSP®
|
Detection Modality |
Time-Resolved Fluorescence (TRF)
|
Disorders |
Cystic Fibrosis
|
Instrument Compatibility |
GSP
|
Quantity |
1152 tests
|
Sample Type |
Dried blood spots
|
Technology |
DELFIA
|
Unit Size |
1 kit
|
Are you looking for resources, click on the resource type to explore further.
We are here to answer your questions.